In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors?

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors?

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors? 


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis